Other Clinical Trial - Long Non Coding RNA in Complications NCT03185767

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Recruiting

the precise role of RNA in setting of this complication in systemic lupus erythematosus (SLE) is largely unknown

Recruitment information / eligibility
Status	Recruiting
Enrollment	100
Est. completion date	July 1, 2017
Est. primary completion date	June 30, 2017
Accepts healthy volunteers	Accepts Healthy Volunteers
Gender	All
Age group	18 Years to 60 Years
Eligibility	Inclusion Criteria: - with systemic lupus Exclusion Criteria: vasculitis

Other:
• blood sampling
blood sampling

Locations
Country	Name	City	State
Egypt	Cairo University	Cairo

Sponsors *(1)*
Lead Sponsor	Collaborator
Cairo University

Egypt,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	non coding RNA expression by real time PCR	non coding RNA expression by real time PCR to evaluate thier role in lupus	1 year